Advertisement

History of GIST

  • Christina L. Roland
  • Barry W. Feig
Chapter

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and historically were associated with a poor prognosis. Advances in the last 20 years in the diagnosis and treatment of GISTs have led to significant improvements in outcomes, making the treatment of GIST a model for the development of targeted therapy for solid tumors. Historically, GIST were classified as gastrointestinal leiomyoma, leiomyosarcoma, or leiomyoblastomas, but were reclassified in the 1990s after demonstration of the cell of origin as the interstitial cells of Cajal and the driver mutation in c-kit. Two years after the identification of c-kit as the activating mutation in GIST, the first patient with advanced GIST was treated on a clinical trial with imatinib, a tyrosine kinase receptor inhibitor of KIT. Today, imatinib is approved for use in advanced/metastatic GIST and as adjuvant therapy. Future advances require an understanding of the molecular biology of when imatinib is ineffective, which will open opportunities for new treatments.

Keywords

Gastrointestinal stromal tumors Imatinib Tyrosine kinase inhibitor Sarcoma c-kit 

Abbreviations

GIST

Gastrointestinal stromal tumor

TKI

Tyrosine kinase inhibitor

References

  1. 1.
    Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc’h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983;7(6):507–19.CrossRefPubMedGoogle Scholar
  4. 4.
    Miettinen M. Gastrointestinal stromal tumors. An immunohistochemical study of cellular differentiation. Am J Clin Pathol. 1988;89(5):601–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992;215(1):68–77.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol. 1995;2(1):26–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.CrossRefPubMedGoogle Scholar
  8. 8.
    O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.CrossRefPubMedGoogle Scholar
  9. 9.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(4):626–32.CrossRefGoogle Scholar
  11. 11.
    Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–34.CrossRefPubMedGoogle Scholar
  12. 12.
    Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72.CrossRefPubMedGoogle Scholar
  14. 14.
    NCT00867113. Five year adjuvant imatinib mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST). 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT00867113?term=GIST+5+year&rank=2.
  15. 15.
    Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.CrossRefPubMedGoogle Scholar
  16. 16.
    Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of Surgical OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations